Stock Scorer

Relay Therapeutics, Inc. (RLAY)

Relay Therapeutics, Inc. reported revenue of 350K USD for the quarter ending 30 June 2026, down 48.3% from 677K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 350K -48.3%
Operating Income Q2 '26 · ending 30 June 2026 -90.8M —
Net Income Q2 '26 · ending 30 June 2026 -83.7M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -54.1M —
Free Cash Flow Q4 '25 · ending 31 December 2025 -44.9M —
Shares Outstanding Q2 '26 · ending 30 June 2026 202.8M +19.9%
EPS Q2 '26 · ending 30 June 2026 -1.56 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 15.4M-302.7M-276.5M-235.9M
20242024-12-31 10M-372.5M-337.7M-251.1M
20232023-12-31 25.5M-373M-342M-304.4M
20222022-12-31 1.4M-299.3M-290.5M-238.6M
20212021-12-31 3M-364.7M-363.9M-77.9M
20202020-12-31 82.7M-55.8M-52.4M-104.4M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-30350K
Q1 '262026-03-313M
Q4 '252025-12-317M
Q3 '252025-09-300
Q2 '252025-06-30677K
Q1 '252025-03-317.7M
Q4 '242024-12-310
Q3 '242024-09-300
Q2 '242024-06-300
Q1 '242024-03-3110M
Q4 '232023-12-31-1K
Q3 '232023-09-3025.2M
Q2 '232023-06-30119K
Q1 '232023-03-31226K
Q4 '222022-12-31253K
Q3 '222022-09-30344K
Q2 '222022-06-30365K
Q1 '222022-03-31419K
Q4 '212021-12-31567K
Q3 '212021-09-30666K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-90.8M
Q1 '262026-03-31-78.6M
Q4 '252025-12-31-60.6M
Q3 '252025-09-30-80.4M
Q2 '252025-06-30-76.8M
Q1 '252025-03-31-84.9M
Q4 '242024-12-31-85M
Q3 '242024-09-30-96.4M
Q2 '242024-06-30-100.8M
Q1 '242024-03-31-90.4M
Q4 '232023-12-31-92.2M
Q3 '232023-09-30-73.6M
Q2 '232023-06-30-106M
Q1 '232023-03-31-101.2M
Q4 '222022-12-31-72.9M
Q3 '222022-09-30-85.9M
Q2 '222022-06-30-77.8M
Q1 '222022-03-31-62.7M
Q4 '212021-12-31-67.7M
Q3 '212021-09-30-61M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-83.7M
Q1 '262026-03-31-73.3M
Q4 '252025-12-31-54.9M
Q3 '252025-09-30-74.1M
Q2 '252025-06-30-70.4M
Q1 '252025-03-31-77.1M
Q4 '242024-12-31-76M
Q3 '242024-09-30-88.1M
Q2 '242024-06-30-92.2M
Q1 '242024-03-31-81.4M
Q4 '232023-12-31-83.5M
Q3 '232023-09-30-65.7M
Q2 '232023-06-30-98.5M
Q1 '232023-03-31-94.2M
Q4 '222022-12-31-67.5M
Q3 '222022-09-30-84.2M
Q2 '222022-06-30-76.8M
Q1 '222022-03-31-62M
Q4 '212021-12-31-67.5M
Q3 '212021-09-30-60.8M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-54.1M
Q1 '262026-03-31-51.1M
Q4 '252025-12-31-44.9M
Q3 '252025-09-30-62.1M
Q2 '252025-06-30-55.3M
Q1 '252025-03-31-73.2M
Q4 '242024-12-31-57.9M
Q3 '242024-09-30-75.1M
Q2 '242024-06-30-65.8M
Q1 '242024-03-31-50.3M
Q4 '232023-12-31-89.2M
Q3 '232023-09-30-75.4M
Q2 '232023-06-30-68.6M
Q1 '232023-03-31-67.1M
Q4 '222022-12-31-57.1M
Q3 '222022-09-30-66.1M
Q2 '222022-06-30-57.1M
Q1 '222022-03-31-49.2M
Q4 '212021-12-31-39.7M
Q3 '212021-09-30-53.2M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q4 '252025-12-31-44.9M
Q3 '252025-09-30-62.1M
Q2 '252025-06-30-55.3M
Q1 '252025-03-31-73.6M
Q4 '242024-12-31-57.9M
Q3 '242024-09-30-75.3M
Q2 '242024-06-30-65.8M
Q1 '242024-03-31-52.1M
Q4 '232023-12-31-89.3M
Q3 '232023-09-30-76M
Q2 '232023-06-30-70.1M
Q1 '232023-03-31-69M
Q4 '222022-12-31-59.4M
Q3 '222022-09-30-68.2M
Q2 '222022-06-30-59M
Q1 '222022-03-31-52M
Q4 '212021-12-31-40.6M
Q3 '212021-09-30-54.9M
Q2 '212021-06-30-28.5M
Q1 '212021-03-3146.2M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30202.8M
Q1 '262026-03-31179.8M
Q3 '252025-09-30172.4M
Q2 '252025-06-30171.3M
Q1 '252025-03-31169.2M
Q3 '242024-09-30140.2M
Q2 '242024-06-30132.8M
Q1 '242024-03-31130.8M
Q3 '232023-09-30122.2M
Q2 '232023-06-30121.7M
Q1 '232023-03-31121.3M
Q3 '222022-09-30110.9M
Q2 '222022-06-30108.6M
Q1 '222022-03-31108.3M
Q3 '212021-09-3092.7M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-1.56
Q1 '262026-03-31-1.56
Q4 '252025-12-31-1.61
Q3 '252025-09-30-1.72
Q2 '252025-06-30-1.92
Q1 '252025-03-31-2.20
Q4 '242024-12-31-2.36
Q3 '242024-09-30-2.61
Q2 '242024-06-30-2.52
Q1 '242024-03-31-2.64
Q4 '232023-12-31-2.80
Q3 '232023-09-30-2.68
Q2 '232023-06-30-2.90
Q1 '232023-03-31-2.80
Q4 '222022-12-31-2.59
Q3 '222022-09-30-2.66
Q2 '222022-06-30-2.56
Q1 '222022-03-31-3.95
Q4 '212021-12-31-3.85
Q3 '212021-09-306.42